Latest Regulatory Milestones News

Galan Lithium Limited advances its Hombre Muerto West project with a new mining permit and a significant resource upgrade at Candelas, positioning itself among the global lithium leaders and targeting production in H1 2026.

Western Gold Resources Limited has secured expanded mining approvals, confirmed strong metallurgical recoveries, and updated its mineral resource estimate at the Gold Duke Project, positioning the company for a transition to production.

Prescient Therapeutics has secured FDA clearance for its PTX-100 Phase 2 trial targeting relapsed/refractory cutaneous T-cell lymphoma, while also appointing James McDonnell as its new CEO. The company reports steady progress in its cell therapy platforms and maintains a solid cash position bolstered by a recent R&D tax rebate.

Elsight reported a robust 32% increase in annual revenue for 2024, driven by a strategic pivot towards the defense sector, which now accounts for over half of its total revenue. The company’s expanding customer base and debt elimination position it well for growth in 2025.

Alligator Energy reports significant progress across its uranium portfolio, including regulatory milestones at Samphire and promising drilling results at Big Lake and Nabarlek North, supported by a solid cash position of $20.2 million.

Triton Minerals has secured A$17 million from the sale of a 70% stake in its Mozambique graphite assets, while progressing environmental approvals and unveiling promising high-grade gold and copper results at its new Aucu project.

Echo IQ confirms the material significance of its pre-submission FDA meeting for EchoSolv HF, marking a pivotal step toward US market entry and commercialisation.

Cambium Bio has secured a A$3 million capital raise and achieved FDA Fast Track status for its lead ophthalmology product, Elate Ocular®, setting the stage for Phase 3 trials in mid-2025.

Kaili Resources has streamlined its exploration portfolio by divesting high-cost, low-return tenements and is intensifying efforts in rare earths and precious metals exploration, targeting promising projects in South Australia and Western Australia.

Emyria Limited reports strong progress in its MDMA and psilocybin-assisted therapy programs alongside a successful $2.525 million capital raise, positioning the company for expanded mental health treatment services.

Ark Mines has delivered a significant upgrade to its Sandy Mitchell Rare Earths Project, including a new Mineral Resource Estimate and a completed Scoping Study confirming commercial viability. The company is now preparing for a Pre-Feasibility Study to expand resources and refine project economics.

Clarity Pharmaceuticals reports robust progress in its SECURE trial and secures FDA Fast Track Designation for its diagnostic agent 64Cu-SAR-bisPSMA, underpinning its growth and innovation in prostate cancer treatment.